Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
Manabu FutamuraKazuhiro IshiharaYasuko NagaoAtsuko OgisoYoshimi NiwaTakumi NakadaYoshihiro KawaguchiAi IkawaIwao KumazawaRyutaro MoriMai KitazawaYoshiki HosonoMasashi KunoMana KawajiriAkira NakakamiMakoto TakeuchiAkemi MorikawaYoshihisa TokumaruYasuo KatagiriYoshimasa AsanoYoshinori MushikaToshio ShimokawaNobuhisa MatsuhasihPublished in: Breast cancer (Tokyo, Japan) (2023)
Nab-PTX plus T-mab and P-mab induced a high pCR rate in HER2-positive BC, particularly in the HER2-subtype. Given that AEs are acceptable, this regimen is safe and acceptable as NAC for HER2-positive BC.
Keyphrases
- phase ii
- clinical trial
- neoadjuvant chemotherapy
- open label
- double blind
- locally advanced
- lymph node
- sentinel lymph node
- transcription factor
- metastatic breast cancer
- high glucose
- diabetic rats
- oxidative stress
- randomized controlled trial
- low dose
- squamous cell carcinoma
- placebo controlled
- advanced non small cell lung cancer
- drug induced
- young adults
- early stage
- tyrosine kinase
- real time pcr
- genome wide analysis